The Claim
In adults with overweight or obesity receiving tirzepatide, apitegromab is well tolerated, with no significant difference in the incidence of adverse events or serious adverse events compared to placebo, despite increased systemic exposure to apitegromab.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with overweight or obesity taking tirzepatide, adding apitegromab does not increase the rate of side effects or serious health problems compared to a placebo, even though the body is exposed to higher levels of apitegromab.
See the scientific wording
Apitegromab is well tolerated in adults with overweight or obesity receiving tirzepatide, with no significant difference in adverse events or serious adverse events compared to placebo, despite increased exposure to a novel biologic agent.
Apitegromab binds to inactive myostatin in the blood, stopping it from becoming active. This prevents myostatin from signaling muscles to stop growing, so muscle mass stays stable even when the body is losing weight. The drug does not activate the immune system or damage organs, so no more side effects occur than with a placebo.
What the research says
1 studyAdding this new drug, apitegromab, to tirzepatide didn’t make people sick more often than giving them a dummy pill — even though the new drug builds muscle and stays in the body. So, it’s safe to use alongside tirzepatide.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.